Videos

BioPorto sees 'huge increase' in antibodies sales and 'good and steady' NGAL Test sales

Q1 2021 Report

May 12, 2021

2020 year-end financials and 2021’s anticipated milestones

An Edison interview with Peter Morch Eriksen

March 19, 2021

BioPorto CEO explains why he expects 2021 to be a 'pivotal year'

March 18, 2021

BioPorto expects to submit De Novo FDA application for pediatric use of NGAL kidney test by summer

March 9, 2021

BioPorto maintains sales momentum of NGAL test, begins patient enrollment for coronavirus test

November 19, 2020

CEO Peter Mørck Eriksen og CFO Ole Larsen præsentere Q3 kvartalsregnkabet

November 19, 2020

BioPorto Diagnostics reveals progress on its co-developed 10-minute coronavirus test

September 18, 2020

BioPorto reveals another quarter of strong revenue from sales of its NGAL kidney damage test

August 25, 2020

BioPorto begins enrolling in its clinical study to treat children with severe acute kidney injury

June 25, 2020

BioPorto sees a 67% increase in NGAL-related revenue in its first quarter

May 11, 2020